CoChat
Sign Up
Cited by 19Drug Transport and Resistance MechanismsImmune Response and InflammationReceptor Mechanisms and Signaling

The DOI matches its Crossref record; the references it cites are not checked yet.

Molecular basis of TASL recruitment by the peptide/histidine transporter 1, PHT1

Open access
Custódio, Tânia F., Killer, Maxime, Yu, Dingquan, Puente, Virginia, Teufel, Daniel P., Pautsch, Alexander, Schnapp, Gisela, Grundl, Marc, Kosinski, Jan, Löw, Christian·2023·Nature Communications
DOI 10.1038/s41467-023-41420-5PMC PMC10502012

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

PHT1 is a histidine /oligopeptide transporter with an essential role in Toll-like receptor innate immune responses. It can act as a receptor by recruiting the adaptor protein TASL which leads to type I interferon production via IRF5. Persistent stimulation of this signalling pathway is known to be involved in the pathogenesis of systemic lupus erythematosus (SLE). Understanding how PHT1 recruits TASL at the molecular level, is therefore clinically important for the development of therapeutics against SLE and other autoimmune diseases. Here we present the Cryo-EM structure of PHT1 stabilized in the outward-open conformation. By combining biochemical and structural modeling techniques we propose a model of the PHT1-TASL complex, in which the first 16 N-terminal TASL residues fold into a helical structure that bind in the central cavity of the inward-open conformation of PHT1. This work provides critical insights into the molecular basis of PHT1/TASL mediated type I interferon production.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-41420-5

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

References 82 · Cited by 19

Research works printed but not linked: 75

  1. Parker, J. L. et al. Proton movement and coupling in the POT family of peptide transporters. Proc. Natl Acad. Sci. USA. 114, 13182–13187 (2017). · DOI
  2. Botka, C. W. et al. Human proton/oligopeptide transporter (POT) genes: identification of putative human genes using bioinformatics. AAPS PharmSci 2, 1–22 (2000). · DOI
  3. Daniel, H., Spanier, B., Kottra, G. & Weitz, D. From bacteria to man: archaic proton-dependent peptide transporters at work. Physiology 21, 93–102 (2006). · DOI
  4. Daniel, H. & Kottra, G. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflug. Arch. Eur. J. Physiol. 447, 610–618 (2004). · DOI
  5. Yan, N. Structural biology of the major facilitator superfamily transporters. Annu. Rev. Biophys. 44, 257–283 (2015). · DOI
  6. Drew, D., North, R. A., Nagarathinam, K. & Tanabe, M. Structures and general transport mechanisms by the major facilitator superfamily (MFS). Chem. Rev. 121, 5289–5335 (2021). · DOI
  7. Quistgaard, E. M., Löw, C., Guettou, F. & Nordlund, P. Understanding transport by the major facilitator superfamily (MFS): Structures pave the way. Nat. Rev. Mol. Cell Biol. 17, 123–132 (2016). · DOI
  8. Spanier, B. & Rohm, F. Proton coupled oligopeptide transporter 1 (PepT1) function, regulation, and influence on the intestinal homeostasis. Compr. Physiol. 8, 843–869 (2018). · DOI
  9. Brandsch, M. Drug transport via the intestinal peptide transporter PepT1. Curr. Opin. Pharmacol. 13, 881–887 (2013). · DOI
  10. Meredith, D. & Boyd, C. A. R. Structure and function of eukaryotic peptide transporters. Cell. Mol. Life Sci. 57, 754–778 (2000). · DOI
  11. Theis, S. et al. Synthesis and characterization of high affinity inhibitors of the H+/peptide transporter PEPT2. J. Biol. Chem. 277, 7287–7292 (2002). · DOI
  12. Tamai, I. et al. Improvement of L-dopa absorption by dipeptidyl derivation, utilizing peptide transporter PepT1. J. Pharm. Sci. 87, 1542–1546 (1998). · DOI
  13. Ezra, A. et al. A peptide prodrug approach for improving bisphosphonate oral absorption. J. Med. Chem. 43, 3641–3652 (2000). · DOI
  14. Hu, Y., Song, F., Jiang, H., Nuñez, G. & Smith, D. E. SLC15A2 and SLC15A4 mediate the transport of bacterially- derived Di/Tripeptides to enhance the NOD-dependent immune response in mouse bone marrow-derived macrophages. Physiol. Behav. 201, 652–662 (2018).
  15. Song, F. et al. Regulation and biological role of the peptide/histidine transporter SLC15A3 in Toll-like receptor-mediated inflammatory responses in macrophage. Cell Death Dis. 9, 1–15 (2018). · DOI
  16. Song, F., Hu, Y., Wang, Y., Smith, D. E. & Jiang, H. Functional characterization of human peptide/histidine transporter 1 in stably transfected MDCK cells. Mol. Pharm. 15, 385–393 (2018). · DOI
  17. Bhardwaj, R. K., Herrera-Ruiz, D., Eltoukhy, N., Saad, M. & Knipp, G. T. The functional evaluation of human peptide/histidine transporter 1 (hPHT1) in transiently transfected COS-7 cells. Eur. J. Pharm. Sci. 27, 533–542 (2006). · DOI
  18. Wang, X. X., Hu, Y., Keep, R. F., Toyama-Sorimachi, N. & Smith, D. E. A Novel Role for PHT1 in the disposition of L-histidine in brain: in vitro slice and in vivo pharmacokinetic studies in wildtype and Pht1 null mice. Biochem. Pharmacol. 124, 94–102 (2017). · DOI
  19. Sakata, K. et al. Cloning of a lymphatic peptide/histidine transporter. Biochem. J. 356, 53–60 (2001). · DOI
  20. Sreedharan, S., Stephansson, O., Schiöth, H. B. & Fredriksson, R. Long evolutionary conservation and considerable tissue specificity of several atypical solute carrier transporters. Gene 478, 11–18 (2011). · DOI
  21. Blasius, A. L. et al. Slc15a4, AP-3, and Hermansky-Pudlak syndrome proteins are required for Toll-like receptor signaling in plasmacytoid dendritic cells. Proc. Natl Acad. Sci. USA. 107, 19973–19978 (2010). · DOI
  22. Baccala, R. et al. Essential requirement for IRF8 and SLC15A4 implicates plasmacytoid dendritic cells in the pathogenesis of lupus. Proc. Natl Acad. Sci. USA. 110, 2940–2945 (2013). · DOI
  23. Kobayashi, T. et al. Lysosome biogenesis regulated by the amino-acid transporter SLC15A4 is critical for functional integrity of mast cells. Int. Immunol. 29, 551–566 (2017). · DOI
  24. Sasawatari, S. et al. The solute carrier family 15A4 regulates TLR9 and NOD1 functions in the innate immune system and promotes colitis in mice. Gastroenterology 140, 1513–1525 (2011). · DOI
  25. Kobayashi, T. et al. The histidine transporter SLC15A4 coordinates mTOR-dependent inflammatory responses and pathogenic antibody production. Immunity 41, 375–388 (2014). · DOI
  26. Lee, J. et al. pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling. J. Biol. Chem. 284, 23818–23829 (2009). · DOI
  27. Takeuchi, F. et al. Search for type 2 diabetes susceptibility genes on chromosomes 1q, 3q and 12q. J. Hum. Genet. 53, 314–324 (2008). · DOI
  28. Heinz, L. X. et al. TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7–9. Nature 581, 316–322 (2020). · DOI
  29. Chen, W. et al. Insights into interferon regulatory factor activation from the crystal structure of dimeric IRF5. Nat. Struct. Mol. Biol. 15, 1213–1220 (2008). · DOI
  30. Zhao, B. et al. Structural basis for concerted recruitment and activation of IRF-3 by innate immune adaptor proteins. Proc. Natl Acad. Sci. USA 113, E3403–E3412 (2016).
  31. Killer, M., Wald, J., Pieprzyk, J., Marlovits, T. C. & Löw, C. Structural snapshots of human PepT1 and PepT2 reveal mechanistic insights into substrate and drug transport across epithelial membranes. Sci. Adv. 7, eabk3259 (2021). · DOI · Paper page
  32. Shen, J. et al. Extracellular domain of PepT1 interacts with TM1 to facilitate substrate transport. Structure 30, 1035–1041 (2022). · DOI · Paper page
  33. Parker, J. L. et al. Cryo-EM structure of PepT2 reveals structural basis for proton-coupled peptide and prodrug transport in mammals. Sci. Adv. 7, eabh3355 (2021). · DOI
  34. Lindley, D. J., Carl, S. M., Mowery, S. A. & Knipp, G. T. The evaluation of peptide/histidine Transporter 1 (PHT1) function: uptake kinetics utilizing a COS-7 stably transfected cell line. Rev. Mex. Cienc. Farm. 42, 57–65 (2011).
  35. Yamashita, T. et al. Cloning and functional expression of a brain peptide/histidine transporter. J. Biol. Chem. 272, 10205–10211 (1997). · DOI
  36. Temel, D. B., Landsman, P. & Brader, M. L. Orthogonal methods for characterizing the unfolding of therapeutic monoclonal antibodies: differential scanning calorimetry, isothermal chemical denaturation, and intrinsic fluorescence with concomitant static light scattering. Methods Enzymol. 567, 359–389 (2016). · DOI
  37. Alexander, C. G. et al. Novel microscale approaches for easy, rapid determination of protein stability in academic and commercial settings. Biochim. Biophys. Acta 1844, 2241–2250 (2014). · DOI
  38. Ericsson, U. B., Hallberg, B. M., DeTitta, G. T., Dekker, N. & Nordlund, P. Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal. Biochem. 357, 289–298 (2006). · DOI
  39. Killer, M. et al. Cryo-EM structure of an atypical proton-coupled peptide transporter: di- and tripeptide permease C. Front. Mol. Biosci. 9, 1–15 (2022). · DOI
  40. Zimmermann, I. et al. Generation of synthetic nanobodies against delicate proteins. Nat. Protoc. 15, 1707–1741 (2020). · DOI
  41. Zimmermann, I. et al. Synthetic single domain antibodies for the conformational trapping of membrane proteins. Elife 7, 1–32 (2018). · DOI
  42. Jackson, S. M. et al. Structural basis of small-molecule inhibition of human multidrug transporter ABCG2. Nat. Struct. Mol. Biol. 25, 333–340 (2018). · DOI
  43. Hanson, M. A. et al. A specific cholesterol binding site is established by the 2.8 Å structure of the human β2-adrenergic receptor. Structure 16, 897–905 (2008). · DOI
  44. Ung, K. L. et al. Structures and mechanism of the plant PIN-FORMED auxin transporter. Nature 609, 605–610 (2022). · DOI
  45. Yu, D., Chojnowski, G., Rosenthal, M. & Kosinski, J. AlphaPulldown-a python package for protein-protein interaction screens using AlphaFold-Multimer. Struct. Bioinforma. 39, btac749 (2022). · DOI · Paper page
  46. Karrar, S. & Cunninghame Graham, D. S. Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us. Arthritis Rheumatol. 70, 496–507 (2018). · DOI
  47. Katewa, A. et al. The peptide symporter SLC15a4 is essential for the development of systemic lupus erythematosus in murine models. PLoS One 16, e0244439 (2021). · DOI
  48. Linke, P. et al. An automated microscale thermophoresis screening approach for fragment-based lead discovery. J. Biomol. Screen. 21, 414–421 (2016). · DOI
  49. Schiebel, J. et al. One question, multiple answers: biochemical and biophysical screening methods retrieve deviating fragment hit lists. ChemMedChem 10, 1511–1521 (2015). · DOI
  50. Harris, V. M. et al. Characterization of cxorf21 provides molecular insight into female-bias immune response in SLE pathogenesis. Front. Immunol. 10, 1–11 (2019). · DOI
  51. Daniel, L. C. et al. Chemoproteomics-guided development of SLC15A4 inhibitors with anti- inflammatory activity. bioRxiv https://doi.org/10.1101/2022.10.07.511216 (2022). · DOI
  52. Bonam, S. R., Wang, F. & Muller, S. Lysosomes as a therapeutic target. Nat. Rev. Drug Discov. 18, 923–948 (2019). · DOI
  53. Zhang, H. et al. SLC15A4 controls endolysosomal TLR7-9 responses by recruiting the innate immune adaptor TASL. Cell Rep. 42, 112916 (2023). · DOI
  54. Backliwal, G. et al. Rational vector design and multi-pathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acids Res. 36, e96 (2008). · DOI
  55. Pieprzyk, J., Pazicky, S. & Löw, C. Transient expression of recombinant membrane-eGFP fusion proteins in HEK293 cells. Methods Mol. Biol. 1850, 17–31 (2018). · DOI
  56. Custódio, T. F. et al. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. Nat. Commun. 11, 5588 (2020). · DOI
  57. Scheres, S. H. W. RELION: Implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519–530 (2012). · DOI · Paper page
  58. Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. CryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017). · DOI · Paper page
  59. Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017). · DOI
  60. Rohou, A. & Grigorieff, N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. Struct. Biol. 192, 216–221 (2015). · DOI
  61. Wagner, T. et al. SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. Commun. Biol. 2, 218 (2019). · DOI
  62. Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70–82 (2020). · DOI
  63. Sanchez-Garcia, R. et al. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun. Biol. 4, 874 (2021). · DOI
  64. Williams, C. J. et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 27, 293–315 (2018). · DOI · Paper page
  65. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. & IUCr. Features and development of Coot. Acta Crystallogr. Sect. D. Biol. Crystallogr. 66, 486–501 (2010). · DOI · Paper page
  66. Croll, T. I. ISOLDE: A physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. Sect. D. Struct. Biol. 74, 519–530 (2018). · DOI
  67. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D. Biol. Crystallogr. D66, 213–221 (2010). · DOI · Paper page
  68. Ashkenazy, H. et al. ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules. Nucleic Acids Res. 44, W344–W350 (2016). · DOI · Paper page
  69. Pei, J., Kim, B.-H. & Grishin, N. V. PROMALS3D: a tool for multiple protein sequence and structure alignments. Nucleic Acids Res. 36, 2295–2300 (2008). · DOI
  70. Bond, C. S. & Schüttelkopf, A. W. ALINE: A WYSIWYG protein-sequence alignment editor for publication-quality alignments. Acta Crystallogr. Sect. D. Biol. Crystallogr. D65, 510–512 (2009). · DOI
  71. Tamura, K. et al. MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28, 2731–2739 (2011). · DOI
  72. Malhotra, S., Joseph, A. P., Thiyagalingam, J. & Topf, M. Assessment of protein–protein interfaces in cryo-EM derived assemblies. Nat. Commun. 12, 3399 (2021). · DOI
  73. Kotov, V. et al. In-depth interrogation of protein thermal unfolding data with MoltenProt. Protein Sci. 30, 201–217 (2021). · DOI
  74. Hall, J. A simple model for determining affinity from irreversible thermal shifts. Protein Sci. 28, 1880–1887 (2019). · DOI
  75. Kotov, V. et al. Plasticity of the binding pocket in peptide transporters underpins promiscuous substrate recognition. Cell Rep. 42, 112831 (2023). · DOI · Paper page

Metadata

Authors
Custódio, T. F., Killer, M., Yu, D., Puente, V., Teufel, D. P., Pautsch, A., Schnapp, G., Grundl, M., Kosinski, J., & Löw, C.
Affiliations
  • European Molecular Biology Laboratory (DE)
  • Heidelberg University (DE)
  • Boehringer Ingelheim (Germany) (DE)
Corresponding author
Löw, Christian
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2023-09-14
Volume
14
Issue
1
Pages
5696-5696
ISSN
2041-1723 (ISSN-L)
DOI
10.1038/s41467-023-41420-5
PMC
PMC10502012
OpenAlex
W4386739366
Cited by
19
References
82
Citations by year
2026: 4 · 2025: 5 · 2024: 8 · 2023: 2
FWCI
2.32
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Desy publication database (The Deutsches Elektronen-Synchrotron) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DESY Publication Database (PUBDB) (Deutsches Elektronen-Synchrotron)
Funders
  • Deutsche Forschungsgemeinschaft (INST 152/772-1, INST 152/772-1 | 152/774-1 | 152/775-1 | 152/776-1 | 152/777-1 FUGG, 152/777 -1 FUGG, 152/775-1, INST 152/772-1|152/774-1|152/775-1|152/776-1, 152/774-1, 152/776-1)
  • Bundesministerium für Bildung und Forschung (05K18YEA)
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Keywords
PHT1, Toll-like receptor signaling, type I interferon production, IRF5, systemic lupus erythematosus, transporter conformation, innate immunity, autoimmune disease
MeSH terms
Autoimmune Diseases, Histidine, Humans, Interferon Type I, Lupus Erythematosus, Systemic, Adaptor Proteins, Signal Transducing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review